Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 10571-10576

  Swellam, Menha ^a   El Khazragy, Nashwa ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Childhood ALL; MiRNA; RT PCR

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 146A; MICRORNA 196A; UNCLASSIFIED DRUG; MIRN100 MICRORNA, HUMAN; MIRN146 MICRORNA, HUMAN; MIRN196 MICRORNA, HUMAN; RNA; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC MARKER; HUMAN; LEUKEMOGENESIS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; BLOOD; CASE CONTROL STUDY; GENETICS; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RECEIVER OPERATING CHARACTERISTIC;

ADOLESCENT; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKOCYTE COUNT; MALE; MICRORNAS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA, NEOPLASM; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84957692374     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4948-7     Document Type: Article

References (26)

1. Crazzolara R, Bendall L. Emerging treatments in acute lymphoblastic leukemia. CurrCancer DrugTargets. 2009;9:19–31.
2. Ching-Hon P, Robison L, Thomas AL. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–43.
3. Pui CH. Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc. 2010;109:777–87.
4. Vitale A, Guarini A, Chiaretti S, Foa R. The changing scene of adult acute lymphoblastic leukemia. CurrOpinOncol. 2006;18:652–9.
5. Nguyen HT, Tian G, Murph MM. Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Frontiers in Oncology, doi: 10.3389/fonc.2014.00071, 2014
6. Swellam M, Abdelmaksoud MDE, Mahmoud MS, Ramadan A, Moneem WA, Hefny MM. Aberrant methylation of APC and RARb2 genes in breast cancer patients. IUBMB Life. 2015;67:61–8.
7. Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang Y, et al. Increased expression of microRNA-196a predicts poor prognosis in human ovarian carcinoma. Int J ClinExpPathol. 2015;8:4132–7.
8. Li Q, Liu L, Li W. Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis. Tumour Biol. 2014;35:10467–78.
9. Cui J. MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis. Int J ClinExp Med. 2015;8:1703–14.
10. Oorschot AAD, Kuipers JE, Arentsen-Peters S, Schotte D, De Haas V, Trka J, et al. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2012;58:715–21.
11. Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A, et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia. 2010;24:89–96.
12. de Oliveira JC, Scrideli CA, Brassesco MS, Morales AG, Pezuk JA, QueirozRde P, et al. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk Res. 2012;36:293–8.
13. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, et al. MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene. 2012;31:80–92.
14. Yu H, Lindsay J, Feng ZP, Frankenberg S, Hu Y,Carone D, Shaw G,Pask AJ, O’NeillR, Papenfuss AT, Renfree MB. Evolution of coding and non-coding genes in HOX clusters of a marsupial. BMC Genomics 2012, doi:10.1186/1471-2164-13-251
15. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. Baltimore DmiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208(6):1189–201.
16. Williams AE, Perry MM, Moschos SA, Larner-Svensson HM, Lindsay M. Role of miRNA-146a in the regulation of the innate immune response and cancer. BiochemSoc Trans. 2008;36:1211–5.
17. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60:1065–75.
18. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.
19. Dong C, Ji M, Ji C. microRNAs and their potential target genes in leukemia pathogenesis. Cancer Biol Ther. 2009;8(3):200–5.
20. Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cell Mol Dis. 2010;44:191–7.
21. Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16:991–1006.
22. Schotte D, Lange-Turenhout EAM, Stumpel DJPM,Stam RW, JGCAM Buijs-GladdinesJGCAM, MeijerinkJPP, Pieters R,Boer MLD. “Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia,” Haematologica. 2010; 95:1675–1682. Stam RW, JGCAM Buijs-GladdinesJGCAM, MeijerinkJPP, Pieters R,Boer MLD
23. Duyu M, Durmaz B, Gunduz C, Vergin C, KarapinarYD, Aksoylar S, Kavakli K, Cetingul N, Irken G, Yaman Y, Ozkinay F, Cogulu O. Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia. BioMed Research International Volume 2014, Article ID 967585, 7 pages http://dx.doi.org/10.1155/2014/967585
24. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103:12481–6.
25. Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, et al. Fcγreceptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies. J Biol Chem. 2013;288:26800–9.
26. Coskun E, von der Heide EK, Schlee EC, Kuhnl A, Gokbuget N, Hoelzer D, et al. The role of miRNA-196a and miRNA 196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leukemia Res. 2011;35:208–13.